Nanogen Pharmaceutical Biotechnology
Privately held: no public share price
Assets
(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 3 | Erythropoietin receptor (EPO-R)Biologic (subtype unspecified) | Chronic Kidney Disease |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
No financial reports recorded.